A REWARDING RESEARCH PATHWAY

Literature Cited

1. Krayer O, Goldstein A, Plachte FL. 1944. Studies on physostigmine and related substances. I. Quantitative relation between dosage of physostigmine and inhibition of cholinesterase activity in the blood serum of dogs.. J. Pharmacol. Exp. Ther. 80:8–30 [Google Scholar]
2. Chapman EM, Goldstein A. 1943. The physics of sound with particular relation to examination of the patient.. J. Lab. Clin. Med. 28:1535–41 [Google Scholar]
3. Goldstein A. 1944. The mechanism of enzyme-inhibitor-substrate reactions. Illustrated by the cholinesterase-physostigmine-acetylcholine system.. J. Gen. Physiol. 27:529–80 [Google Scholar]
4. Goldstein A. 1949. A “free manometer” technique for use with the Warburg apparatus.. Science 110:400 [Google Scholar]
5. Goldstein A. 1949. The interactions of drugs and plasma proteins.. Pharmacol. Rev. 1:102–65 [Google Scholar]
6. Luria SE, Delbruck M. 1943. Mutations of bacteria from virus sensitivity to virus resistance.. Genetics 28:491–511 [Google Scholar]
7. Goldstein A, Magasanik B, Umbarger HE. 1955. On the mechanism of development of resistance to streptomycin in. Micrococcus pyogenes Var. Aureus. J. Bacteriol. 70:620–21 [Google Scholar]
8. Goldstein A. 1987. Otto Krayer. In Biographical Memoirs 57150–225 Washington, DC: Natl. Acad. Press [Google Scholar]
9. Goldstein A. 1964. Biostatistics: An Introductory Text. New York: Macmillan 272 pp. [Google Scholar]
10. Watson JD, Crick FHC. 1953. Molecular structure of nucleic acid. A structure for deoxyribose nucleic acid.. Nature 171:737–38 [Google Scholar]
11. Goldstein A, Brown BJ. 1961. Addition of amino acid to C-terminal ends of growing protein chains in Escherichia coli.. Biochim. Biophys. Acta 53:438–39 [Google Scholar]
12. Goldstein A, Kirschbaum JB, Roman A. 1965. Direction of synthesis of messenger RNA in cells of Escherichia coli.. Proc. Natl. Acad. Sci. USA 54:1669–75 [Google Scholar]
13. Riggs DS, Goldstein A. 1961. Equation for inert gas exchange which treats ventilation as cyclic.. J. Applied Physiol. 16:531–37 [Google Scholar]
14. Goldstein A, Aronow L, Kalman SM. 1968. Principles of Drug Action: The Basis of Pharmacology. New York: Hoeber-Harper & Row 884 pp. [Google Scholar]
15. Goldstein A, Warren R, Kaizer S. 1965. Psychotropic effects of caffeine in man. I. Individual differences in sensitivity to caffeine-induced wakefulness.. J. Pharmacol. Exp. Ther. 149:156–59 [Google Scholar]
16. Goldstein A, Kaizer S, Warren R. 1965. Psychotropic effects of caffeine in man. II. Alertness, psychomotor coordination, and mood.. J. Pharmacol. Exp. Ther. 150:146–51 [Google Scholar]
17. Goldstein A, Kaizer S. 1969. Psychotropic effects of caffeine in man. III. A questionnaire survey of coffee drinking and its effects in a group of housewives.. Clin. Pharmacol. Ther. 10:477–88 [Google Scholar]
18. Goldstein A, Kaizer S, Whitby O. 1969. Psychotropic effects of caffeine in man. IV. Quantitative and qualitative differences associated with habituation to coffee.. Clin. Pharmacol. Ther. 10:489–97 [Google Scholar]
19. Dole VP, Nyswander M. 1965. A medical treatment for diacetylmorphine (heroin) addiction.. J. Am. Med. Assoc. 193:80–84 [Google Scholar]
20. Goldstein A, Lowney LI, Pal BK. 1971. Stereospecific and nonspecific interactions of the morphine congener levorphanol in subcellular fractions of mouse brain.. Proc. Natl. Acad. Sci. USA 68:1742–47 [Google Scholar]
21. Pert CB, Snyder SH. 1973. Opiate receptor: demonstration in nervous tissue.. Science 179:1011–14 [Google Scholar]
22. Simon EJ, Hiller JM, Edelman I. 1973. Stereospecific binding of the potent narcotic analgesic 3-etorphine to rat brain homogenate.. Proc. Natl. Acad. Sci. USA 70:1947–49 [Google Scholar]
23. Terenius L. 1973. Stereospecific interaction between narcotic analgesics and a synaptic plasma membrane fraction of rat brain cortex.. Acta Pharmacol. Toxicol. 32:317–20 [Google Scholar]
24. Goldstein A, Herrera J. 1995. Heroin addicts and methadone treatment in Albuquerque: a 22-year follow-up.. Drug Alcohol Depend. 40:139–50 [Google Scholar]
25. Hughes J, Smith TW, Kosterliltz HW, Fothergill LA, Morgan BA, Morris HR. 1975. Identification of two related pentapeptides from the brain with potent opiate agonist activity.. Nature 258:577–79 [Google Scholar]
26. Cox BM, Opheim KE, Teschemacher H, Goldstein A. 1975. A peptide-like substance from pituitary that acts like morphine. 2. Purification and properties.. Life Sci. 16:1777–82 [Google Scholar]
27. Goldstein A, Tachibana S, Lowney LI, Hunkapiller M, Hood L. 1979. Dynorphin-(1-13), an extraordinarily potent opioid peptide.. Proc. Natl. Acad. Sci. USA 76:6666–70 [Google Scholar]
28. Goldstein A, Fischli W, Lowney LI, Hunkapiller M, Hood L. 1981. Porcine pituitary dynorphin: complete amino acid sequence of the biologically active heptadecapeptide.. Proc. Natl. Acad. Sci. USA 78:7219–23 [Google Scholar]
29. Chavkin C, James IF, Goldstein A. 1982. Dynorphin is a specific endogenous ligand of the κ opioid receptor.. Science 215:413–15 [Google Scholar]
30. Goldstein A, Naidu A. 1989. Multiple opioid receptors: ligand selectivity profiles and binding site signatures.. Mol. Pharmacol. 36:265–72 [Google Scholar]
31. Goldstein A, Barrett RW. 1987. Ligand dissociation constants from competition binding assays: errors associated with ligand depletion.. Mol. Pharmacol. 31:603–9 [Google Scholar]
32. Xie GX, Miyajima A, Goldstein A. 1992. Expression cloning of cDNA encoding a seven-helix receptor from human placenta with affinity for opioid ligands.. Proc. Natl. Acad. Sci. USA 89:4124–28 [Google Scholar]
33. Meng F, Xie GX, Thompson RC, Mansour A, Goldstein A. et al. 1993. Cloning and pharmacological characterization of a rat kappa opioid receptor.. Proc. Natl. Acad. Sci. USA 90:9954–58 [Google Scholar]
34. Kieffer BL, Befort K, Gaveriaux-Ruff C, Hirth CG. 1992. The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization.. Proc. Natl. Acad. Sci. USA 89:12048–52 [Google Scholar]
35. Evans CJ, Keith DE Jr, Morrison H, Magendzo K, Edwards RH. 1992. Science 258:1952–55 [Google Scholar]
36. Weitz CJ, Lowney LI, Faull KF, Feistner G, Goldstein A. 1986. Morphine and codeine from mammalian brain.. Proc. Natl. Acad. Sci. USA 83:9784–88 [Google Scholar]
37. Weitz CJ, Lowney LI, Faull KF, Feistner G, Goldstein A. 1988. 6-Acetylmorphine: a natural product present in mammalian brain.. Proc. Natl. Acad. Sci. USA 85:5335–38 [Google Scholar]
38. Judson BA, Himmelberger DU, Goldstein A. 1980. The naloxone test for opiate dependence.. Clin. Pharmacol. Ther. 27:492–501 [Google Scholar]
39. Judson BA, Goldstein A. 1979. Levo-alpha-acetylmethadol (LAAM) in the treatment of heroin addicts. I. Dosage schedule for induction and stabilization.. Drug Alcohol Depend. 4:461–66 [Google Scholar]
40. Judson BA, Goldstein A, Inturrisi CE. 1983. Methadyl acetate (LAAM) in the treatment of heroin addicts. II. Double-blind comparison of gradual and abrupt detoxification.. Arch. Gen. Psychiatry 40:834–40 [Google Scholar]
41. Grevert P, Goldstein A. 1978. Endorphins: naloxone fails to alter experimental pain or mood in humans.. Science 199:1093–95 [Google Scholar]
42. Goldstein A. 1980. Thrills in response to music and other stimuli.. Physiol. Psychol. 8:126–29 [Google Scholar]
43. Leute RK, Ullman EF, Goldstein A, Herzenberg LA. 1972. Spin immunoassay technique for determination of morphine.. Nat. New Biol. (London 236:93–94 [Google Scholar]
44. Goldstein A, Leute RK, Ullman EF. 1972. US Patent No. 3690834
45. Needels MC, Jones DG, Tate EH, Heinkel GL, Kochersperger LM. et al. 1993. Generation and screening of an oligonucleotide-encoded synthetic peptide library.. Proc. Natl. Acad. Sci. USA 90:10700–4 [Google Scholar]
46. Stagsted J, Reaven GM, Hansen T, Goldstein A, Olsson L. 1990. Regulation of insulin receptor functions by a peptide derived from a major histocompatibility complex class I antigen.. Cell 62:297–307 [Google Scholar]
47. Hooke LP, He L, Lee NM. 1995. [Des-Tyr1]dynorphin A-(2-17) has naloxone- insensitive antinociceptive effect in the writhing assay.. J. Pharmacol. Exp. Ther. 273:802–7 [Google Scholar]
48. Goldstein A. 1978. IFR Principles and Practice: A Guide to Safe Instrument Flying. Long Beach, CA: Airguide 124 pp. [Google Scholar]
49. Goldstein A. 1984. Flying Out of Danger: A Pilot's Guide to Safety. Long Beach, CA: Airguide 140 pp. [Google Scholar]
50. Goldstein A. 1986. VFR Flight Review: A Guide to Better Flying. Stanford, CA: AvvA 267 pp. [Google Scholar]
51. Goldstein A. 1986. The Right Seat: An Introduction to Flying for Pilots' Companions and Would-be Pilots. Stanford, CA: AvvA 145 pp. [Google Scholar]
52. Chen XH, Han JS. 1992. All three types of opioid receptors in the spinal cord are important for 2/15 Hz electroacupuncture analgesia.. Eur. J. Pharmacol. 211:203–10 [Google Scholar]
53. Goldstein A. 1994. ADDICTION: From Biology to Drug Policy. New York: Freeman 321 pp. [Google Scholar]
54. Goldstein A, Kalant H. 1990. Drug policy: striking the right balance.. Science 249:1513–21 [Google Scholar]